Effect of vitamin D supplementation in the treatment of polycystic ovary syndrome

The effects of vitamin D supplementation on hormonal profiles, inflammatory factors, oxidative stress biomarkers and gene expression related to inflammation in women with polycystic ovary syndrome candidates for IVF

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170513033941N53

Enrollment

Registered

2019-03-29

Start date

2018-12-17

Completion date

Unknown

Last updated

2019-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: 50000 IU vitamin D every weeks (Zahravi, Tabriz, Iran), for 8 weeks orally. Intervention 2: Control group: Placebo (Barij Essence, Kashan, Iran) every weeks, for 8

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with polycystic ovary syndrome candidates for IVF Individuals aged 18 to 40 years.

Exclusion criteria

Exclusion criteria: Exclusion criteria: Individuals with neoplastic disorders cardiovascular diseases malabsorptive disorders current or previous (within the last 6 months) use of hormonal; antidiabetic and anti-obesity medications.

Design outcomes

Primary

Measure	Time frame
Total testosterone. Timepoint: En At the beginning of the study and after 8 weeks of intervention. Method of measurement: Elisa kit.;SHBG. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Elisa kit.	—

Secondary

Measure	Time frame
Hs-CRP. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Elisa kit.;Nitric oxide. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Expressed levels of TNF-a gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.;Expressed levels of IL-1 gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.;Expressed levels of IL-8 gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.	—

Measure

Time frame

Hs-CRP. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Elisa kit.;Nitric oxide. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Expressed levels of TNF-a gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.;Expressed levels of IL-1 gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.;Expressed levels of IL-8 gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_z@kaums.ac.ir+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026